Opsonophagocytic killing activity of rabbit antibody to Pseudomonas aeruginosa mucoid exopolysaccharide

We used an in vitro opsonophagocytic killing assay to measure the functional activity of antibody directed at the mucoid exopolysaccharide (MEP) antigen expressed by Pseudomonas aeruginosa strains isolated from cystic fibrosis patients. Rabbit antibodies raised to purified MEP were able to mediate phagocytic killing in the presence of human peripheral blood leukocytes and a low level (final concentration, 0.3%) of fresh normal human serum as a complement source. No bacterial killing was observed when peripheral blood leukocytes, antiserum, or complement was omitted. Specificity of the antibody for the MEP antigen was shown by adsorption and inhibition assays. Affinity-purified antibody to MEP also mediate phagocytic killing. These data indicate that antiphagocytic properties attributable to MEP can be overcome by specific antibody.

[1]  G. Pier,et al.  Mediation of the killing of rough, mucoid isolates of Pseudomonas aeruginosa from patients with cystic fibrosis by the alternative pathway of complement. , 1984, The Journal of infectious diseases.

[2]  G. Pier,et al.  Nonspecific immunoglobulin synthesis and elevated IgG levels in rabbits immunized with mucoid exopolysaccharide from cystic fibrosis isolates of Pseudomonas aeruginosa. , 1984, Journal of immunology.

[3]  J. Gee,et al.  Proteins of the cystic fibrosis respiratory tract. Fragmented immunoglobulin G opsonic antibody causing defective opsonophagocytosis. , 1984, The Journal of clinical investigation.

[4]  L. Mutharia,et al.  Antibody to Pseudomonas Aeruginosa Mucoid Exopolysaccharide and to Sodium Alginate in Cystic Fibrosis Serum , 1984, Pediatric Research.

[5]  R. Hancock,et al.  Pseudomonas aeruginosa isolates from patients with cystic fibrosis: a class of serum-sensitive, nontypable strains deficient in lipopolysaccharide O side chains , 1983, Infection and immunity.

[6]  G. Pier,et al.  Characterization of the human immune response to a polysaccharide vaccine from Pseudomonas aeruginosa. , 1983, The Journal of infectious diseases.

[7]  G. Pier,et al.  Immunochemical characterization of the mucoid exopolysaccharide of Pseudomonas aeruginosa. , 1983, The Journal of infectious diseases.

[8]  G. Pier.  Safety and immunogenicity of high molecular weight polysaccharide vaccine from immunotype 1 Pseudomonas aeruginosa. , 1982, The Journal of clinical investigation.

[9]  R. Matthay,et al.  Cystic fibrosis pseudomonas opsonins. Inhibitory nature in an in vitro phagocytic assay. , 1981, The Journal of clinical investigation.

[10]  P. di Sant'Agnese,et al.  Cystic fibrosis in adults: 75 cases and a review of 232 cases in the literature , 1979 .

[11]  J. Verhoef,et al.  Complement-mediated phagocytosis of Pseudomonas aeruginosa. , 1978, The Journal of laboratory and clinical medicine.

[12]  J. Verhoef,et al.  Kinetics of staphylococcal opsonization, attachment, ingestion and killing by human polymorphonuclear leukocytes: a quantitative assay using [3H]thymidine labeled bacteria. , 1977, Journal of immunological methods.

[13]  L. Young,et al.  Human immunity to Pseudomonas aeruginosa. I. In-vitro interaction of bacteria, polymorphonuclear leukocytes, and serum factors. , 1972, The Journal of infectious diseases.

[14]  S. Schwarzmann,et al.  Antiphagocytic Effect of Slime from a Mucoid Strain of Pseudomonas aeruginosa , 1971, Infection and immunity.

[15]  D. M. Carlson,et al.  Polyuronic acids produced by Pseudomonas aeruginosa. , 1966, Biochemistry.